Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

26.62 +0.06 (+0.23%)
Official Closing Price Updated: 7:00 PM EST, Dec 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
Tuesday Talk: Still Flying
The stock market is still on the upswing. For all the anti-Fed pundits, the market seems to be going with Chairman Powell for now. 
Via Talk Markets
Pfizer's Options Frenzy: What You Need to Know
Via Benzinga
Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields
Investing in high-yield dividend stocks under $50 is a low-risk strategy that can result in massive returns in time. 
Via InvestorPlace
What's Going With BioNTech Stock On Monday?
BioNTech reports Q1 loss, missing revenue expectations. Despite challenges, BioNTech aims for significant growth, fueled by innovative R&D and strong cash reserves. 
Via Benzinga
Pfizer Announces New Chief Strategy and Innovation Officer
From Pfizer Inc.
Via Business Wire
Pfizer Unusual Options Activity
Via Benzinga
Pfizer's Stock Is a Buy. Here Are Six Reasons Why.
The pharma-giant's shares could be poised for a trend reversal. 
Via The Motley Fool
Pfizer Finds a Foothold After a Solid Q1 2024 Earnings Report
After a painful two-year selloff, Pfizer shareholders may have finally gained a foothold after the company delivered a solid Q1 2024 earnings report 
Via MarketBeat
Exposures COVID-19
How this baseball All-Star steps up to the plate when it comes to pneumococcal pneumonia
(BPT) - Professional baseball player JD Martinez is at increased risk for pneumococcal pneumonia because he has asthma, and he doesn't want to let it stop him from taking his shot on - or off - the... 
Via Brandpoint
Revive Your Portfolio: 3 Undervalued Stocks Poised for Growth
While big splashes of red ink represent danger, for contrarian investors, these undervalued growth stocks may spell opportunity. 
Via InvestorPlace
3 No-Brainer Stocks to Buy in May
These great stocks are great picks for investors as spring winds down. 
Via The Motley Fool
Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?
Where there's a will, there's a way. And Pfizer appears to have the will to stake a claim in the massive obesity drug market. 
Via The Motley Fool
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
These highly advantaged businesses have what they need to keep raising their dividend payouts. 
Via The Motley Fool
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance. 
Via Investor's Business Daily
Topics Economy
Exposures Interest Rates
3 Ultra-Safe Stocks to Buy So You Can Rest Easy in Any Market
Defensive stocks are increasingly safe to buy and attractive as volatility rises and indices fall at large, making time tested shares hot. 
Via InvestorPlace
Pfizer Prospects Garner Mixed Sentiment From Analysts: 'Finally, The Pivot Investors Have Been Waiting For'
Pfizer analysts from Goldman see a positive outlook on Padcev, Prevnar, and Vindaqel, but Nurtec and Oxbryta execution needs work. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
3 Contrarian Stocks That Could Make You a Fortune (If You Dare)
Sometimes the best way to invest your money is in the companies no one is bullish about, just like these three contrarian stocks to buy. 
Via InvestorPlace
Moderna Puts Up Big Quarterly Beat; Could Shares Notch A Breakout?
Moderna is forming its first base in over a year. Could shares top a buy point on the company's sales beat? 
Via Investor's Business Daily
My Top 5 Favorite High-Yield Dividend Stocks to Buy in May
Income investors can buy in May and go away with these stocks. 
Via The Motley Fool
Thoughts For Thursday: Lingering Inflation
The Fed had expected to lower interest rates by now, but according to Chairman Powell, inflation is sticking around longer than expected and therefore higher rates will stick around longer, too. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Investor Optimism Improves Slightly Following Fed Decision
Via Benzinga
Topics Economy
Exposures Interest Rates
Carvana, Enovix, Pfizer, Nio, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Wednesday saw a mixed performance in major U.S. indices. The Dow Jones Industrial Average closed the day with a 0.2% increase at 37,903.29. 
Via Benzinga
Topics Stocks
Exposures US Equities
Pfizer (PFE) Q1 2024 Earnings Call Transcript
PFE earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Pfizer Stock Blasted More Than 6% Higher Today
A double beat on earnings, plus raised bottom-line guidance, made the company a hot item on Hump Day. 
Via The Motley Fool
Dow Jumps 200 Points Following Fed Decision; Pfizer Earnings Top Estimates
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
US Stocks Mixed Ahead Of Fed Meeting, Chipmakers Tumble After AMD Earnings, Bitcoin Sinks: What's Driving Markets Wednesday?
Traders are treading cautiously in Wednesday’s session, seeking more clarity on the Federal Reserve’s stance with inflation reports exceeding expectations. 
Via Benzinga
Topics Economy
Exposures Interest Rates
PFE Stock Earnings: Pfizer Beats EPS, Beats Revenue for Q1 2024
PFE stock results show that Pfizer beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Pfizer Q1 Earnings and Revenues Beat Estimates
PFE came out with quarterly earnings of $0.82 per share, beating the our eimate of $0.56 per share. This compares to earnings of $1.23 per share a year ago. 
Via Talk Markets
Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To Perform Consistently With Expectations
Pfizer reports Q1 results: adjusted EPS beats estimates, driven by revenue growth. Significant declines in Comirnaty and Paxlovid revenues countered by operational gains. Company announces plans for... 
Via Benzinga
Exposures COVID-19
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.